Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Human iPSC-derived bone marrow organoids for AML engraftment and immunotherapy testing

View Full Paper
Ask AI
Bookmark
Share

Authors

IGIsabel GoekMLMonika I. LinderBVBinje Vick

Discussion

Loading...

Member takes

Overview

Observational analysis shows improved survival of leukemic stem cells in bone marrow organoids, highlighting potential for immunotherapy testing.

Key Points

  • The use of iPSC-derived bone marrow organoids supports the engraftment and proliferation of diverse AML subtypes.
  • A five-fold increase in labeled, CD34+ cells was observed by day 15 in the organoid system for AML cells.
  • Targeted immunotherapy testing demonstrated effective T-cell-mediated killing against AML cells in the model.
  • These organoids provide a complex human microenvironment essential for examining leukemia-niche interactions in therapy development.

Cite This Study

Goek et al. (2025) studied this question.

synapsesocial.com/papers/69362f364fa91c937236d376https://doi.org/10.1182/blood-2025-4960
View Full Paper
Ask AI
Bookmark
Share